Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Darolutamide with ADT and Radiation in Prostate Cancer
NCT05116475Phase 3Recruiting
- Sponsor
- ARTIC
- Start
- Aug 2022
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide Arm with Placebo Arm (2 arms). Primary endpoint: Failure-Free Survival at 3 years. Started Aug 2022; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05116475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116475.